Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
RATIONALE Nicotinic α7 acetylcholine receptors (nAChRs) have been highlighted as a target for cognitive enhancement in schizophrenia. AIM To investigate whether the deficits induced by sub-chronic phencyclidine (PCP) in reversal learning and novel object recognition could be attenuated by the selective α7 nAChR full agonist, PNU-282987. METHODS Adult female hooded-Lister rats received sub-chronic PCP (2mg/kg) or vehicle i.p. twice daily for 7days, followed by 7 days washout. In cohort 1, PCP-treated rats then received PNU-282987 (5, 10, 20mg/kg; s.c.) or vehicle and were tested in the reversal-learning task. In cohort 2, PCP-treated rats received PNU-282987 (10mg/kg; s.c.) or saline for 15days and were tested in the novel object recognition test on day 1 and on day 15, to test for tolerance. RESULTS Sub-chronic PCP produced significant deficits in both cognitive tasks (P<0.01-0.001). PNU-282987 attenuated the PCP-induced deficits in reversal learning at 10mg/kg (P<0.01) and 20mg/kg (P<0.001), and in novel object recognition at 10mg/kg on day 1 (P<0.01) and on day 15 (P<0.001). CONCLUSIONS These data show that PNU-282987 has efficacy to reverse PCP-induced deficits in two paradigms of relevance to schizophrenia. Results further suggest that 15-day once daily dosing of PNU-282987 (10mg/kg s.c.) does not cause tolerance in the rat. This study suggests that activation of α7 nAChRs, may represent a suitable strategy for improving cognitive deficits of relevance to schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.023 · Cited by 919
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678 · cited 2×
“The most prevalent nAChRs in the brain are the α4β2 and α7 subtypes, both of which have been shown to have reduced numbers in post-mortem studies of schizophrenia patients (Breese et al., 2000; Freedman et al., 1995).”
Dias, R., Robbins, T. W., & Roberts, A. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-23-09285.1997 · Cited by 555 · cited 7×
“Although the mechanism for the effect of PCP is not yet established; recent work from our laboratory showed that the PCP-induced deficit is accompanied by impaired dopamine neurotransmission in the PFC during the retention trial of the task (Snigdha et al., 2008).”
InfluentialAbdul-Monim, Z., Neill, J. C., & Reynolds, G. P. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107067097 · Cited by 206 · cited 2×
“, 2010); and that these deficits are accompanied by reductions in parvalbumin-immunoreactive neurons in the hippocampus and M1 (motor area 1) region of the frontal cortex (Abdul-Monim et al., 2007) and brain-derived neurotrophic factor (BDNF) levels in several cortical regions (Snigdha et al.”
Self-citationTAIT, D. S., & BROWN, V. J. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1401.010 · Cited by 75
Idris, N., Neill, J., Grayson, B., Bang-Andersen, B., Witten, L. M., Brennum, L. T., & Arnt, J. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1702-5 · Cited by 74 · cited 5×
“, 2008; 2010) and the ethologically relevant, novel object recognition task (Grayson et al., 2007; Idris et al., 2009; McLean et al., 2009a).”
InfluentialSelf-citation
Cited by
Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 530
Self-citationAlzarea, S., & Rahman, S. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.03.019 · Cited by 75
Young, J. W., Meves, J. M., & Geyer, M. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.11.028 · Cited by 69
Janhunen, S. K., Svärd, H., Talpos, J., Kumar, G., Steckler, T., Plath, N., Lerdrup, L., Ruby, T., Haman, M., Wyler, R., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3954-6 · Cited by 43
“Another task frequently used in the literature where performance deficits were detected following cessation of scPCP administration is the novel object recognition (NOR) task (Grayson et al. 2007; Idris et al. 2010; McLean et al. 2011) (Table 1).”
BackgroundInfluentialMcLean, S. L., Harte, M. K., Neill, J. C., & Young, A. M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117704988 · Cited by 16
Self-citation
Metadata
- Authors
- McLean, S. L., Grayson, B., Idris, N. F., Lesage, A. S., Pemberton, D. J., Mackie, C., & Neill, J. C.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 21
- Issue
- 4
- Pages
- 333-343
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2034413002
- Cited by
- 60
- References
- 6
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia. https://app.cochat.ai/papers/10.1016/j.euroneuro.2010.06.003
- The paper
- McLean, S. L., Grayson, B., Idris, N. F., Lesage, A. S., Pemberton, D. J., Mackie, C., & Neill, J. C. (2011). Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2010.06.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.